TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of “Hold” by Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has earned an average recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.60.

A number of research firms have recently weighed in on TCRX. Morgan Stanley downgraded shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a report on Thursday, January 22nd. BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 4th. Needham & Company LLC decreased their price target on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Finally, HC Wainwright dropped their price target on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, November 13th.

TScan Therapeutics Trading Down 1.9%

Shares of TScan Therapeutics stock opened at $1.02 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. The firm has a 50-day moving average of $1.06 and a 200-day moving average of $1.52. TScan Therapeutics has a 52-week low of $0.88 and a 52-week high of $2.67. The stock has a market cap of $57.89 million, a PE ratio of -0.91 and a beta of 1.04.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.07. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. The business had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $1.98 million. As a group, sell-side analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Activity at TScan Therapeutics

In other news, major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was bought at an average price of $0.90 per share, with a total value of $72,062.10. Following the acquisition, the insider owned 7,937,416 shares in the company, valued at approximately $7,143,674.40. The trade was a 1.02% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have purchased 161,801 shares of company stock valued at $145,621. 4.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Aberdeen Group plc lifted its stake in TScan Therapeutics by 31.8% during the fourth quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock worth $1,785,000 after purchasing an additional 430,421 shares during the last quarter. Voleon Capital Management LP acquired a new position in shares of TScan Therapeutics during the 3rd quarter worth $87,000. Citadel Advisors LLC raised its holdings in shares of TScan Therapeutics by 78.4% during the 3rd quarter. Citadel Advisors LLC now owns 390,747 shares of the company’s stock worth $711,000 after buying an additional 171,760 shares in the last quarter. Virtu Financial LLC lifted its position in shares of TScan Therapeutics by 431.1% during the 3rd quarter. Virtu Financial LLC now owns 60,480 shares of the company’s stock worth $110,000 after buying an additional 49,092 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in TScan Therapeutics by 14.9% in the third quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock valued at $763,000 after buying an additional 54,370 shares in the last quarter. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.